Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1328 Neoplasms 998 Carcinoma, Non-Small-Cell Lung 865 Prostatic Neoplasms 730 Colorectal Neoplasms 671 Lung Neoplasms 553 Leukemia, Myeloid, Acute 475 Neoplasm Metastasis 427 Pancreatic Neoplasms 426 Carcinoma, Hepatocellular 407 Ovarian Neoplasms 393 Multiple Myeloma 393 Stomach Neoplasms 383 Recurrence 369 Squamous Cell Carcinoma of Head and Neck 327 Melanoma 295 Uterine Cervical Neoplasms 288 Brain Neoplasms 288 Triple Negative Breast Neoplasms 273 Glioblastoma 263 Head and Neck Neoplasms 260 Precursor Cell Lymphoblastic Leukemia-Lymphoma 256 Endometrial Neoplasms 238 Lymphoma 230 Esophageal Neoplasms 226 Rectal Neoplasms 224 Sarcoma 213 Carcinoma, Renal Cell 205 Colonic Neoplasms 196 Lymphoma, Large B-Cell, Diffuse 194

Interventions

sintilimab 1 pyrotinib 1 palbociclib 1 niraparib 1 dacomitinib 1 aumolertinib 1 atezolizumab 1 alectinib 1 Vemurafenib 1 Imatinib Mesylate 1 Crizotinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Interventional × Rare Tumor × Clear all

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting

Rare Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡